3 Unstoppable Growth Stocks to Buy Right Now

A recent broad correction has created entry points in high-growth technology stocks, despite strong operational progress from many companies. Among these, Symbotic (SYM) stands out with $592 million in Q3 FY25 revenue and a $22.4 billion contracted backlog in warehouse automation, while AST SpaceMobile (ASTS) reported $14.7 million in Q3 2025 revenue and over $1 billion in contracted commitments for its space-based cellular network. Additionally, SS Innovations International (SSII) is advancing its robotic surgery systems with over 100 installations and an anticipated Q4 2025 FDA 510(k) filing. These firms, despite recent share price declines of 5-14%, are noted for their strong fundamentals, competitive advantages, and near-term catalysts, positioning them for potential outperformance as market sentiment recovers.

Analysis

A recent broad market correction has led to significant 15-30% drawdowns in high-growth technology stocks over the past 30 days, despite many companies reporting strong operational progress. This widespread sell-off presents potential entry points for investors seeking fundamentally sound companies with clear competitive advantages and upcoming catalysts. The general market sentiment is moderately positive, albeit speculative, regarding these opportunities.

Symbotic (SYM), a leader in warehouse automation, reported Q3 FY25 revenue of $592 million, a 26% year-over-year increase, with adjusted EBITDA rising to $45 million from $3 million. The company holds a substantial contracted backlog of $22.4 billion, primarily tied to long-term rollouts with Walmart and GreenBox, offering multiyear revenue visibility. Despite a 14% decline in its share price over the last month, the underlying operational strength and backlog suggest the sell-off is driven by near-term concerns rather than collapsing demand.

AST SpaceMobile (ASTS) is progressing towards commercialization of its space-based cellular network, with Q3 2025 revenue reaching $14.7 million, a notable increase from $1.1 million a year prior, supported by government contracts. The company maintains H2 2025 revenue guidance of $50 million to $75 million and has secured over $1 billion in contracted revenue commitments, alongside $3.2 billion in pro forma cash for satellite deployment. However, execution and launch timelines remain critical swing factors, especially after missing Q3 revenue expectations.

SS Innovations International (SSII) is transitioning to scale in robotic surgery, having installed over 100 SSi Mantra systems and completed more than 5,000 procedures without device-related adverse events. A key near-term catalyst is the expected Q4 2025 510(k) premarket notification filing for FDA clearance, a potentially faster regulatory pathway. The appointment of Dr. Frederic Moll, founder of Intuitive Surgical, as vice chairman further validates the platform, despite the stock experiencing a modest 5% decline over the past 30 days.

Key Decisions for Investors

• Investors should consider the recent tech correction as a potential entry point for fundamentally strong companies like Symbotic, AST SpaceMobile, and SS Innovations International, focusing on their substantial backlogs, revenue growth, and upcoming catalysts.
• Monitor execution risks and regulatory timelines, particularly for ASTS's satellite launches and SSII's FDA clearance, as these are critical for near-term volatility and long-term value creation.
• Evaluate the long-term competitive advantages and market opportunities presented by these innovative technologies against their current valuations, especially given the recent share price pullbacks.